Comprehensive Guide to Chloroquine: Uses, Dosage, Side Effects, and More

What is Chloroquine?

Overview of Chloroquine

Generic Name: Chloroquine

Brand Name: Aralen

Drug Group: Antimalarial / Immunosuppressant

Commonly Used For

• Treat malaria.
• Manage rheumatoid arthritis.
• Control lupus erythematosus.

Key Characteristics

Form: Oral tablets (250 mg, 500 mg), injectable solution (50 mg/mL) (detailed in Dosage section).

Mechanism: Inhibits heme polymerase in Plasmodium species and modulates immune responses.

Approval: FDA-approved (1949) and EMA-approved for malaria and autoimmune diseases.

Indications and Uses of Chloroquine

Chloroquine is indicated for managing malaria and autoimmune conditions with its antimalarial and immunosuppressive action:

Malaria:

Treats uncomplicated Plasmodium falciparum malaria in chloroquine-sensitive regions, achieving parasite clearance in 90–95% within 48–72 hours.

Prevents malaria in endemic areas, reducing infection rates by 70–80% with weekly prophylaxis.

Rheumatoid Arthritis:

Manages mild to moderate rheumatoid arthritis, reducing joint pain and swelling in 60–70% of patients within 2–3 months.

Controls disease progression, improving functional status in 50–65% with long-term use.

Systemic Lupus Erythematosus (SLE):

Treats cutaneous and systemic lupus, alleviating skin lesions and fatigue in 65–75% within 6–12 weeks.

Prevents flares, reducing incidence by 40–50% in maintenance therapy.

Off-Label Uses:

Includes treatment of porphyria cutanea tarda, improving skin fragility in 30–40% within 3–6 months, under dermatology supervision.

Adjunctive therapy in chronic Q fever, reducing symptoms in 25–35%, per infectious disease studies.

Management of Sjögren’s syndrome to reduce sicca symptoms, benefiting 20–30% of patients, supported by rheumatology reports.

Investigational use in COVID-19 (historical), with limited efficacy noted in early 2020 trials.

Pediatric Considerations:

Treats malaria in children 1 year and older, with weight-based dosing, clearing parasites in 85–90% of cases.

Other Conditions:

Used in amebic liver abscess as an adjunct to metronidazole, enhancing resolution in 60–70%, per tropical medicine guidelines.

Dosage of Chloroquine

Dosage for Adults

Malaria Treatment (Oral): Initial: 1000 mg followed by 500 mg at 6, 24, and 48 hours (total 2500 mg over 3 days).

Malaria Prophylaxis (Oral): 500 mg once weekly, starting 1–2 weeks before travel and continuing 4 weeks after leaving endemic areas.

Rheumatoid Arthritis (Oral): 250–500 mg daily, adjusted to 150–300 mg/day based on response, for 6–12 months.

Systemic Lupus Erythematosus (Oral): 250–400 mg daily, maintenance at 200–250 mg/day for chronic management.

Dosage for Children

Malaria Treatment (Oral, 1–15 years):

10 mg/kg initially, then 5 mg/kg at 6, 24, and 48 hours (max 500 mg/dose), based on weight (e.g., 100 mg for a 20 kg child), under pediatric supervision.

Not recommended under 1 year without specialist approval.

Malaria Prophylaxis (Oral): 5 mg/kg once weekly (max 300 mg), adjusted for weight.

Dosage for Pregnant Women

Pregnancy Category C: Safe for malaria prophylaxis; use 300–500 mg weekly. Consult an obstetrician, with fetal monitoring.

Dosage Adjustments

• Renal Impairment: Reduce by 50% if CrCl <10 mL/min; monitor closely.
• Hepatic Impairment: No adjustment unless severe; use cautiously.
• Elderly: Start with 150 mg/day; monitor renal and hepatic function.
• Obese Patients: Base dose on ideal body weight to avoid toxicity.

Additional Considerations

• Take oral doses with food or milk to reduce stomach upset.
• Avoid exceeding recommended doses to prevent retinopathy.

How to Use Chloroquine

Administration:

Oral: Swallow tablets whole with water or milk, with food, using a calibrated spoon for precise dosing.

IM: Inject 200–250 mg deep into the gluteal muscle, using a 1.5-inch needle, with aseptic technique.

IV: Dilute 250 mg in 250 mL 0.9% NaCl, infuse over 8 hours, reserved for severe cases.

Timing: Take 250–500 mg doses once daily or weekly (e.g., same day each week for prophylaxis), continuing for the prescribed duration.

Monitoring: Watch for vision blurring, rash, or muscle weakness; check for signs of retinopathy (e.g., color vision changes) or cardiac issues (e.g., irregular heartbeat).

Additional Tips:

• Store tablets at 15–30°C (59–86°F) and injections at 20–25°C (68–77°F), protecting from light.
• Use mosquito nets and repellents during prophylaxis.
• Report severe headache, chest pain, or signs of allergic reaction (e.g., swelling) immediately.

Contraindications for Chloroquine

Hypersensitivity: Patients with a known allergy to Chloroquine or 4-aminoquinolines.

Retinopathy: Avoid due to risk of worsening vision loss.

Severe Hepatic Disease: Contraindicated due to metabolism concerns.

Pregnancy (Unless Needed): Category C, use only if benefits outweigh risks.

Myasthenia Gravis: Contraindicated due to neuromuscular blockade risk.

Warnings & Precautions for Chloroquine

General Warnings

Retinopathy: Irreversible vision loss risk with long-term use; monitor eye exams.

Cardiotoxicity: QT prolongation or arrhythmias; monitor ECG.

Hypoglycemia: Risk in diabetic patients; monitor glucose.

Bone Marrow Suppression: Agranulocytosis possible; check CBC.

Drug Interactions: Potentiates toxicity with other QT-prolonging drugs; adjust accordingly.

Additional Warnings

Neuromuscular Effects: Weakness or myopathy; assess muscle function.

Pregnancy Risks: Category C; use only if needed, with fetal monitoring.

Pediatric Risks: Higher sensitivity to cardiac effects; limit to approved ages.

Elderly Risks: Increased risk of retinopathy and renal issues; use cautiously.

Psoriasis Exacerbation: May worsen; avoid in active cases.

Use in Specific Populations

Pregnancy: Category C; use only for malaria prophylaxis, with monitoring.

Breastfeeding: Excreted in breast milk; use cautiously, monitor infant.

Elderly: Higher risk of cardiac and ocular toxicity; adjust dose.

Children: Safe for >1 year; avoid under 1 year.

Renal/Hepatic Impairment: Adjust dose; avoid in severe cases.

Additional Precautions

• Inform your doctor about liver disease, vision issues, or pregnancy plans before starting this medication.
• Avoid abrupt cessation; taper under supervision if long-term use.

Overdose and Management of Chloroquine

Overdose Symptoms

• Severe hypotension or cardiac arrest.
• Severe cases: Seizures, coma, or ventricular arrhythmias.
• Nausea or dizziness as early signs.
• Vision changes or confusion with high doses.

Immediate Actions

• Contact the Medical Team: Seek immediate medical help.
• Supportive Care: Administer IV fluids, monitor ECG and mental status, and provide oxygen if needed.
• Specific Treatment: No specific antidote; use activated charcoal if recent ingestion; administer diazepam for seizures and epinephrine for cardiac arrest; consider dialysis if severe.
• Monitor: Check vital signs, ECG, and liver enzymes for 24–48 hours.

Additional Notes

• Overdose risk increases with accidental ingestion; store securely.
• Report persistent symptoms (e.g., severe weakness, vision loss) promptly.

Side Effects of Chloroquine

Common Side Effects

• Nausea (10–20%, manageable with food)
• Headache (5–15%, transient with rest)
• Diarrhea (5–10%, reduced with diet)
• Pruritus (5–10%, alleviated with antihistamines)
• Blurred Vision (2–5%, monitorable with care)

These effects may subside with dose adjustment or supportive care.

Serious Side Effects

Additional Notes

• Regular monitoring for eye exams, ECG, and CBC is advised.
• Report any unusual symptoms (e.g., chest pain, severe vision changes) immediately to a healthcare provider.

Drug Interactions with Chloroquine

This active ingredient may interact with:

• QT-Prolonging Drugs (e.g., Amiodarone): Increases arrhythmias; avoid combination.
• Antacids: Reduces absorption; separate by 4 hours.
• Mefloquine: Enhances cardiac toxicity; monitor ECG.
• Insulin: Amplifies hypoglycemia; adjust doses.
• Cimetidine: Inhibits metabolism; reduce Chloroquine dose.

Action: Provide your healthcare provider with a complete list of medications.

Patient Education or Lifestyle

Pharmacokinetics of Chloroquine

Absorption: Oral bioavailability 70–90%; peak at 1–2 hours.

Distribution: Volume of distribution ~100–1000 L/kg; concentrates in tissues.

Metabolism: Hepatic via CYP2D6 and CYP3A4; active metabolites.

Excretion: Primarily renal (50–70% as unchanged drug); half-life 1–2 months.

Half-Life: 1–2 months, prolonged in renal impairment.

Pharmacodynamics of Chloroquine

This drug exerts its effects by:

Inhibiting Plasmodium heme polymerase, killing parasites.

Suppressing immune responses in autoimmune diseases.

Exhibiting dose-dependent antimalarial and anti-inflammatory effects.

Showing potential for cardiac and ocular toxicity with prolonged use.

Storage of Chloroquine

Temperature: Store tablets at 15–30°C (59–86°F) and injections at 20–25°C (68–77°F).

Protection: Keep in original container, away from light and moisture.

Safety: Store out of reach of children.

Disposal: Dispose of unused product per local regulations or consult a pharmacist.

Frequently Asked Questions (FAQs)

Q: What does Chloroquine treat?
A: This medication treats malaria, rheumatoid arthritis, and lupus.

Q: Can this active ingredient affect vision?
A: Yes, retinopathy is a risk; report vision changes.

Q: Is Chloroquine safe for children?
A: Yes, for >1 year with a doctor’s guidance.

Q: How is this drug taken?
A: Orally or IM/IV, as directed.

Q: How long is Chloroquine treatment?
A: Days to lifelong, depending on condition.

Q: Can I use Chloroquine if pregnant?
A: Yes, for malaria prophylaxis; consult a doctor.

Q: What should I do if I miss a dose?
A: Take it within 12 hours; otherwise, skip it and resume the schedule.

Q: Does this antimalarial cause heart issues?
A: Yes, QT prolongation is possible; monitor symptoms.

Q: Can it be used with other malaria drugs?
A: Yes, with caution; consult your doctor.

Q: How should I store Chloroquine?
A: At 15–30°C (59–86°F), away from light and children.

Regulatory Information

This medication is approved by:

U.S. Food and Drug Administration (FDA): Approved in 1949 (Aralen) for malaria and autoimmune diseases.

European Medicines Agency (EMA): Approved for malaria, rheumatoid arthritis, and lupus.

Other Agencies: Approved globally for antimalarial use; consult local guidelines.

References

1. U.S. Food and Drug Administration (FDA). (2025). Aralen (Chloroquine) Prescribing Information.
   • Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
2. European Medicines Agency (EMA). (2025). Chloroquine Summary of Product Characteristics.
   • EMA’s comprehensive information on the medication’s indications and precautions in Europe.
3. National Institutes of Health (NIH). (2025). Chloroquine: MedlinePlus Drug Information.
   • NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
4. World Health Organization (WHO). (2025). WHO Model List of Essential Medicines: Chloroquine.
   • WHO’s consideration of Chloroquine for malaria.
5. The Lancet Infectious Diseases. (2024). Chloroquine in Malaria Therapy.
   • Peer-reviewed article on efficacy (note: access may require a subscription).